VectorY Therapeutics combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need. Here are details of VectorY‘s latest funding round :
🚀 Launch
2020
🏭 Industry
Biotechnology
🧠Management
Sander van Deventer (CEO)
💸 Funding & Investors
INVESTMENT (Novembre 2023) | €129 million (Series A) |
INVESTORS (Novembre 2023) | co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund. New and existing investors also participated in the round, including MRL Ventures Fund, Rahway, NJ USA, Insight Partners, ALS Investment Fund, Forbion Ventures, BioGeneration Ventures (BGV) and another known investor. |
🎯 Funding purpose
Support the clinical development of VTx-002, its lead vectorized antibody program targeting TDP-43 for ALS treatment.
🌐 Country HQ
The Netherlands (Amsterdam)